Buprenorphine as a pharmacotherapy for cocaine abuse: a review of the evidence.
The partial mu-opiate agonist, buprenorphine, is the subject of recent evaluation as a potential pharmacotherapy for cocaine dependence. This paper reviews the extant preclinical and clinical evidence of buprenorphine effectiveness in treating cocaine abuse, including data from our large methadone comparison trial and a smaller buprenorphine dose ranging study. Although buprenorphine appears to reduce cocaine self-administration in studies of non-opiate dependent animals, clinical evidence for the same response in opiate addicts abusing cocaine has not been demonstrated. Further efficacy trials should await preclinical demonstrations of effectiveness in samples with opiate and cocaine exposure.
Compton
P A
PA
Los Angeles Addiction Treatment Research Center 90025, USA.
Ling
W
W
Charuvastra
V C
VC
Wesson
D R
DR
D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000627:therapeutic use*; D002047:Buprenorphine / Q000008:administration & dosage / Q000627:therapeutic use*; D003042:Cocaine; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008691:Methadone / Q000008:administration & dosage / Q000627:therapeutic use; D019966:Substance-Related Disorders / Q000534:rehabilitation*
D000701:Analgesics, Opioid; D002047:Buprenorphine; D003042:Cocaine; D008691:Methadone